Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma"

Affiliations

Comment

Lijun Zhang et al. Hepatobiliary Surg Nutr. 2016 Oct.

. 2016 Oct;5(5):444-446.

doi: 10.21037/hbsn.2016.10.01.

¹ Department of General Surgery, Beijing Tongren Hospital, Beijing 100730, China.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Combination treatment including targeted therapy for advanced hepatocellular carcinoma.
Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Lin J, et al. Oncotarget. 2016 Oct 25;7(43):71036-71051. doi: 10.18632/oncotarget.11954. Oncotarget. 2016. PMID: 27626176 Free PMC article. Review.

1. Lin J, Wu L, Bai X, et al. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016. [Epub ahead of print]. - PMC - PubMed
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. 10.3322/caac.21254 - DOI - PubMed
1. Ronot M, Bouattour M, Wassermann J, et al. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014;19:394-402. 10.1634/theoncologist.2013-0114 - DOI - PMC - PubMed
1. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502-9; discussion 509-11. 10.1097/SLA.0b013e318148c704 - DOI - PMC - PubMed
1. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72. 10.1016/S1470-2045(08)70206-7 - DOI - PubMed